Zenacts Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 09-12-2024
- Paid Up Capital ₹ 2.00 M
as on 09-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.90 Cr
as on 09-12-2024
- Revenue -7.84%
(FY 2023)
- Profit 0.83%
(FY 2023)
- Ebitda 935.00%
(FY 2023)
- Net Worth 17.76%
(FY 2023)
- Total Assets 7.23%
(FY 2023)
About Zenacts Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹2.90 Cr.
Cheena Kapoor and Pankaj Kumar serve as directors at the Company.
- CIN/LLPIN
U24232CH2013PTC034396
- Company No.
034396
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zenacts Pharma Private Limited offer?
Zenacts Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Common Disease Medicines, Cough Syrup, Pharmaceutical Medicine, Digestive System Drugs & Medicines, Antacid Drugs, Antiemetic, Pharma & Bioanalytical Services, PCD Pharma Franchise.
Who are the key members and board of directors at Zenacts Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Cheena Kapoor  | Director | 21-Jan-2023 | Current |
| Pankaj Kumar | Director | 20-Mar-2013 | Current |
Financial Performance of Zenacts Pharma.
Zenacts Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.84% decrease. The company also saw a slight improvement in profitability, with a 0.83% increase in profit. The company's net worth Soared by an impressive increase of 17.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zenacts Pharma?
In 2023, Zenacts Pharma had a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 30 Nov 2022 | ₹2.90 Cr | Open |
How Many Employees Work at Zenacts Pharma?
Zenacts Pharma has a workforce of 3 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenacts Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenacts Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
